Profile: BeyondSpring Inc (BYSI.OQ)

BYSI.OQ on NASDAQ Stock Exchange Capital Market

15 Nov 2019
Change (% chg)

-- (--)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

BeyondSpring Inc. is a global clinical-stage biopharmaceutical company. The Company is focused on the development of cancer therapies. The Company is engaged in advancing its lead product, Plinabulin, into a Phase II/III clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase II/III clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia, and a Phase III clinical trial as an anticancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC). Plinabulin has also entered in a Phase I/II clinical trials to investigate its therapeutic potential in combination with the immuno-oncology agent nivolumab.

The Company's product, Plinabulin, is a marine derived small-molecule with a range of biological activities. Plinabulin targets cells in the tumor vasculature resulting in selective anti-tumor activity. Plinabulin has also demonstrated a range of immuno-stimulatory effects, including stimulating the maturation of dendritic cells, increasing cytokine secretion, down regulating inhibitory T-cells, and stimulating tumor-antigen-specific T-cell activation. The Company's BPI-002 program is based on an oral small molecule agent, which induces T-cell activation. The Company's IkappaB kinase (IKK) program, BPI-003, is based on a small molecule inhibitor of IKK, a protein kinase. IKK is involved in survival of some tumor cells, as well as in the production of a range of cytokines and growth factors that serve as survival factors for various tumors.

Company Address

BeyondSpring Inc

28 Liberty St Fl 39
NEW YORK   NY   10005-1451
P: +1646.5284184

Company Web Links